All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is pleased to present a visual abstract representing data from a phase II trial (NCT02663622) evaluating CD24Fc, a novel CD24 fusion protein, for graft-versus-host disease prophylaxis.1
This study, which was conducted in two parts (a double-blind dose-escalation phase and an open-label extension phase), evaluated the safety, recommended dose, and efficacy of CD24Fc in patients undergoing allogeneic hematopoietic stem cell transplantation.1 Overall, CD24Fc demonstrated improved graft-versus-host disease-free survival compared with matched controls, and no patients experienced dose-limiting toxicities.1
Your opinion matters
Subscribe to get the best content related to GvHD delivered to your inbox